CORONA Remedies Limited — PPTs, 31-07-2026: Investor Presentation

**CORONA Remedies Q1 FY27 Performance**

**Business Performance:**

CORONA Remedies reported strong Q1 FY27 results, with revenue growing 21.9% YoY to INR 422.4 Cr. This growth was primarily driven by its chronic and sub-chronic therapies, which now account for approximately 73.4% of revenue. The company continues to outpace the Indian Pharmaceutical Market (IPM) growth, improving its ranking to 26th.

**Growth Drivers & Strategy:**

A key strategic move was the inauguration of a new EU-GMP certified Hormone Facility at their Bhayla plant, expanding their women's healthcare offerings. The company's focused brand-building approach and "engine brands" strategy continue to drive market share gains.

**Recent Developments:**

The company renewed its EU-GMP certification for the Oral Solid Dosage facility at the Bhayla plant and successfully launched its state-of-the-art Hormone Manufacturing Facility there.

**Key Financial Metrics:**

EBITDA saw a significant jump of 33.5% YoY to INR 93.1 Cr, with an improved EBITDA margin of 22.0%. Profit After Tax (PAT) grew 30.1% YoY to INR 60.1 Cr, with PAT margin at 14.2%.

**Management Commentary / Outlook:**

CORONA is focused on increasing market share by improving MR productivity and intensifying engagement with specialist prescribers. They also plan to expand into new therapeutic areas and leverage acquisitions for sustainable growth. The company sees significant growth potential in the Indian Pharmaceutical Market, driven by demographic shifts and increasing health awareness.